News headlines about Myriad Genetics (NASDAQ:MYGN) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Myriad Genetics earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.7215657867894 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news stories that may have effected Accern’s rankings:
- Myriad Genetics (MYGN) Rating Lowered to Hold at BidaskClub (americanbankingnews.com)
- Barclays Cuts Myriad Genetics (MYGN) Price Target to $26.00 (americanbankingnews.com)
- Taking a Look at the Data Behind – iQIYI, Inc., NASDAQ: IQ), Myriad Genetics, Inc., (NASDAQ: MYGN) (dailynysenews.com)
- Myriad Genetics, Inc. (MYGN) Reaches $28.18 After 3.00% Down Move; Profile of 5 Analysts Covering EnPro … (mtastar.com)
- A worth reading Analysis of Myriad Genetics, Inc. (NASDAQ:MYGN) (oracleexaminer.com)
A number of equities research analysts have commented on MYGN shares. Goldman Sachs started coverage on Myriad Genetics in a report on Monday, January 29th. They set a “sell” rating and a $32.00 target price on the stock. Barclays increased their target price on Myriad Genetics from $30.00 to $35.00 and gave the company an “equal weight” rating in a report on Monday, January 22nd. Stephens set a $45.00 target price on Myriad Genetics and gave the company a “buy” rating in a report on Wednesday, January 3rd. BidaskClub upgraded Myriad Genetics from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 20th. Finally, ValuEngine cut Myriad Genetics from a “buy” rating to a “hold” rating in a report on Tuesday, March 13th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $30.75.
Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.07. Myriad Genetics had a return on equity of 9.59% and a net margin of 16.67%. The company had revenue of $194.00 million for the quarter, compared to analyst estimates of $188.72 million. During the same quarter in the prior year, the company posted $0.26 EPS. The business’s revenue for the quarter was down 1.3% compared to the same quarter last year. analysts expect that Myriad Genetics will post 1.15 earnings per share for the current fiscal year.
In other Myriad Genetics news, VP Gary A. King sold 3,120 shares of the stock in a transaction on Thursday, January 18th. The stock was sold at an average price of $38.12, for a total transaction of $118,934.40. Following the transaction, the vice president now owns 125,088 shares of the company’s stock, valued at approximately $4,768,354.56. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Richard M. Marsh sold 37,654 shares of the stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $40.25, for a total value of $1,515,573.50. Following the transaction, the vice president now directly owns 157,648 shares in the company, valued at approximately $6,345,332. The disclosure for this sale can be found here. Corporate insiders own 6.70% of the company’s stock.
WARNING: This piece was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.chaffeybreeze.com/2018/04/16/myriad-genetics-mygn-earning-somewhat-favorable-media-coverage-accern-reports.html.
About Myriad Genetics
Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.